CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH) studied in research contexts for its ability to stimulate growth hormone secretion. It is classified as a research use only compound and is used in laboratory settings to investigate the mechanisms of the GHRH receptor pathway and downstream hormonal signaling.
This guide covers the chemical profile of CJC-1295, its research applications, relevant study findings, and what qualified researchers should know when sourcing this compound.
Chemical Profile and Mechanism
CJC-1295 is a 30-amino acid peptide that binds to and activates the GHRH receptor on pituitary somatotroph cells. Its primary mechanism involves stimulating the pulsatile release of growth hormone from the anterior pituitary gland. Unlike native GHRH, which has a short plasma half-life due to rapid enzymatic degradation, CJC-1295 was developed with modifications to extend its active duration in research models.
The drug affinity complex (DAC) version of CJC-1295 incorporates a lysine residue modification that allows covalent binding to serum albumin, significantly extending its half-life compared to the non-DAC form. Both versions are studied in research contexts, though they exhibit different pharmacokinetic profiles that affect experimental design.
Molecular formula: C152H252N44O42 Molecular weight: 3367.97 g/mol Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Research Applications
CJC-1295 is investigated across several research domains:
Growth Hormone Axis Research — Studies examining the regulation of growth hormone secretion use CJC-1295 to stimulate controlled GH release in experimental models. Research in this area investigates the feedback mechanisms between GHRH, somatostatin, and pituitary somatotrophs.
Metabolic Research — Growth hormone plays a central role in glucose metabolism, lipid oxidation, and protein synthesis. CJC-1295 is used in research models studying how GH axis stimulation affects these metabolic parameters.
Body Composition Studies — Preclinical research has examined the relationship between GH stimulation via CJC-1295 and changes in lean mass and fat distribution in animal models.
IGF-1 Pathway Investigation — CJC-1295 stimulates GH release which in turn triggers IGF-1 production in the liver. Research using CJC-1295 frequently examines the downstream IGF-1 response as a primary outcome measure.
Key Research Findings
Published research on CJC-1295 has characterized its pharmacokinetic profile and hormonal effects in human subjects and animal models. Studies have documented mean GH concentrations following administration and examined the duration of elevated GH and IGF-1 levels in response to single and repeated dosing protocols.
Research has also compared the DAC and non-DAC forms, noting differences in peak GH response timing, sustained elevation duration, and receptor occupancy patterns. These pharmacokinetic distinctions are relevant for researchers designing experimental protocols that require specific GH response profiles.
Purity and Quality Considerations
For research use, CJC-1295 should be sourced at verified purity levels with full analytical documentation. Given its 30-amino acid length, synthesis complexity is higher than shorter peptides, and purity verification via HPLC and mass spectrometry is particularly important.
Researchers should look for lot-specific Certificates of Analysis that include HPLC chromatograms showing purity percentage and mass spectrometry data confirming the correct molecular weight. Generic purity claims without supporting analytical data are insufficient for research-grade sourcing decisions.
Proper storage of lyophilized CJC-1295 is at -20°C with protection from light and moisture. Reconstituted peptide should be stored at 4°C and used within an appropriate timeframe to maintain stability.
Sourcing for Research Use
CJC-1295 is designated for research use only. It is not approved for human or animal consumption, is not a pharmaceutical product, and is not intended for diagnostic or therapeutic application. Qualified researchers and laboratory purchasers should verify that their intended use aligns with research use only guidelines before ordering.
Nextday Peptides provides research-grade peptides including CJC-1295 with HPLC-verified purity and lot-specific COA documentation. All compounds are fulfilled from U.S. inventory with expedited shipping options to support research timelines.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC? CJC-1295 with DAC incorporates a modification that allows it to bind to serum albumin, extending its half-life in research models. The non-DAC version has a shorter active duration. Both are studied in research contexts but exhibit different pharmacokinetic profiles.
What purity level is appropriate for CJC-1295 research? Research applications typically use CJC-1295 at 98% or higher HPLC purity. For quantitative studies or publication-quality research, 99% purity is standard.
What documentation should accompany research-grade CJC-1295? A complete Certificate of Analysis including HPLC chromatogram with purity percentage and mass spectrometry data confirming molecular weight. Lot-specific documentation is preferred over generic specification sheets.
How should CJC-1295 be stored? Lyophilized powder should be stored at -20°C away from light and moisture. Once reconstituted, store at 4°C and use within a short timeframe to maintain peptide integrity.
Is CJC-1295 approved for human use? No. CJC-1295 is a research use only compound and is not approved for human or animal consumption, diagnostic use, or therapeutic application.
For research use only. Not for human or animal consumption. Not intended for diagnostic or therapeutic use. All information is provided for educational and research purposes only.
